Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,865
archived clinical trials in
Multiple Sclerosis

Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
Thomas Jefferson University Physicians
mi
from
Philadelphia, PA
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
Thomas Jefferson University Physicians
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
The Neurological Research center, Inc
mi
from
Bennington, VT
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
The Neurological Research center, Inc
mi
from
Bennington, VT
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
Fletcher Allen Health Care
mi
from
Burlington, VT
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
MS Center at Evergreen
mi
from
Kirkland, WA
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
MS Center at Evergreen
mi
from
Kirkland, WA
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
CAMC Health Education and Research Institute
mi
from
Charleston, WV
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
Center for Neurological Disorders of Aurora, St. Luke's Medical Center
mi
from
Milwaukee, WI
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
Center for Neurological Disorders of Aurora, St. Luke's Medical Center
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated:  1/4/2016
Foothills Medical Center
mi
from
Calgary,
Study of Fampridine-SR Tablets in Multiple Sclerosis Patients
Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate Safety and Efficacy of Oral Fampridine-SR (10 mg b.i.d. [Bis in Die, Twice Daily]) in Patients With Multiple Sclerosis
Status: Enrolling
Updated: 1/4/2016
Foothills Medical Center
mi
from
Calgary,
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Birmingham, AL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Cullman, AL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Cullman, AL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Tucaloosa, AL
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Tucaloosa, AL
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Anchorage, AK
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Anchorage, AK
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Flagstaff, AZ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Flagstaff, AZ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Gilbert, AZ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Gilbert, AZ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Phoenix, AZ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Tucson, AZ
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fayetteville, AR
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fayetteville, AR
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Little Rock, AR
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Sherwood, AR
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Sherwood, AR
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Auburn, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Auburn, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Berkeley, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Berkeley, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Carmel, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Carmel, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Carmichael, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Carmichael, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fountain Valley, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fresno, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fresno, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Fullerton, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Fullerton, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
La Jolla, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
La Jolla, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Loma Linda, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Loma Linda, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Los Alamitos, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Los Angeles, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Marina Del Rey, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Marina Del Rey, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Modesto, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Modesto, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Newport Beach, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Newport Beach, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Northridge, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Palo Alto, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Palo Alto, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Pasadena, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Pasadena, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Redding, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Redding, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Sacramento, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
San Diego, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
San Francisco, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
San Francisco, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Santa Barbara, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Santa Barbara, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
St. Helena, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
St. Helena, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Stanford, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Stanford, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Stockton, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Stockton, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Thousand Oaks, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Tracy, CA
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Tracy, CA
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Arvada, CO
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Arvada, CO
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Aurora, CO
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Aurora, CO
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Research Site
mi
from
Basalt, CO
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Research Site
mi
from
Basalt, CO
Click here to add this to my saved trials
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated:  1/14/2016
Clinical Research Facility
mi
from
Centennial, CO
JC Virus Antibody Study of Participants With Relapsing Forms of MS Receiving Treatment With Natalizumab
JCV Antibody Program in Patients With Relapsing Multiple Sclerosis Receiving or Considering Treatment With Tysabri: STRATIFY-2
Status: Enrolling
Updated: 1/14/2016
Clinical Research Facility
mi
from
Centennial, CO
Click here to add this to my saved trials